Published in Proc Natl Acad Sci U S A on April 26, 1994
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol (1998) 3.23
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol (1995) 2.35
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines (2006) 1.88
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol (2008) 1.71
Laboratory-directed protein evolution. Microbiol Mol Biol Rev (2005) 1.69
Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol (2008) 1.64
Exploring the functional robustness of an enzyme by in vitro evolution. EMBO J (1996) 1.38
Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog (2014) 1.32
Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis (1999) 1.29
In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope. J Virol (1996) 1.28
Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. J Virol (2001) 1.26
Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A (2012) 1.18
Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Virol (2003) 1.18
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol (2010) 1.14
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J Virol (2013) 1.13
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog (2010) 1.10
Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci U S A (2008) 1.09
Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. J Virol (1996) 1.03
Vaccinology: precisely tuned antibodies nab HIV. Nature (2011) 1.03
Lipid nanotubes as substrates for helical crystallization of macromolecules. Proc Natl Acad Sci U S A (1998) 1.00
Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization. Nat Biotechnol (2010) 0.97
Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol (2008) 0.94
Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med (1998) 0.93
Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis. Infect Immun (1999) 0.90
Improving the species cross-reactivity of an antibody using computational design. Bioorg Med Chem Lett (2009) 0.90
Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One (2012) 0.89
Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proc Natl Acad Sci U S A (1997) 0.86
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries. Proc Natl Acad Sci U S A (1995) 0.85
Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent. MAbs (2010) 0.84
Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS (2015) 0.83
Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody. Protein Sci (2009) 0.81
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol (2013) 0.81
The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs (2014) 0.80
Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther (2010) 0.80
Tailored amino acid diversity for the evolution of antibody affinity. MAbs (2012) 0.79
Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop. Cell Mol Biol (Noisy-le-grand) (2012) 0.78
Directed evolution of an anti-human red blood cell antibody. MAbs (2010) 0.77
Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Hum Antibodies (2012) 0.77
Receptor binding domain based HIV vaccines. Biomed Res Int (2015) 0.76
Phages and HIV-1: from display to interplay. Int J Mol Sci (2012) 0.76
Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines. Viruses (2014) 0.75
The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. Virology (2014) 0.75
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A (1991) 5.94
Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science (1993) 5.40
Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol (1991) 4.82
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods (1991) 4.34
Additivity of mutational effects in proteins. Biochemistry (1990) 4.05
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol (1993) 3.95
Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses (1987) 3.67
HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 3.37
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1992) 2.98
A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. Res Virol (1992) 2.74
Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol (1993) 2.42
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol (1994) 2.40
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (1991) 2.28
Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci U S A (1993) 2.01
Major antigen-induced domain rearrangements in an antibody. Structure (1993) 1.99
Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94
Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A (1992) 1.93
Selecting high-affinity binding proteins by monovalent phage display. Biochemistry (1991) 1.66
Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1994) 1.57
Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin. Nature (1991) 1.47
Comparative studies on use of fresh and frozen peripheral blood lymphocyte specimens for isolation of human immunodeficiency virus and effects of cell lysis on isolation efficiency. J Clin Microbiol (1987) 1.47
Antibodies without immunization. Science (1992) 1.41
Selection of human anti-hapten antibodies from semisynthetic libraries. Gene (1993) 1.23
Determination of kinetic constants for the interaction between a monoclonal antibody and peptides using surface plasmon resonance. Biochemistry (1992) 1.11
Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J Clin Microbiol (1990) 1.10
High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. Proc Natl Acad Sci U S A (1993) 1.06
Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration. AIDS (1994) 1.04
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A (1991) 5.94
Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis (1985) 5.91
Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science (1989) 5.73
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science (2001) 5.39
The role of the receptionist in general practice: a 'dragon behind the desk'? Soc Sci Med (1985) 3.80
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med (1997) 3.63
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS (1999) 3.57
Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol (2001) 3.39
HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 3.37
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
The antiviral activity of antibodies in vitro and in vivo. Adv Immunol (2001) 3.29
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol (1998) 3.23
Enzyme-linked immunosorbent assay for detection of respiratory syncytial virus infection: application to clinical samples. J Clin Microbiol (1982) 3.22
Immunoglobulin G: functional sites. Mol Immunol (1985) 3.12
Organising a practice. Changes in home visiting and night and weekend cover: the patient's view. Br Med J (Clin Res Ed) (1982) 3.10
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1992) 2.98
A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. J Mol Biol (1997) 2.95
Effectiveness of laser therapy and topical desensitising agents in treating dentine hypersensitivity: a systematic review. J Oral Rehabil (2011) 2.91
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Changes in general practice: do patients benefit? Br Med J (Clin Res Ed) (1981) 2.82
Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 2.78
gp120: Biologic aspects of structural features. Annu Rev Immunol (2001) 2.70
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity (1999) 2.67
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol (1990) 2.65
Mapping the prion protein using recombinant antibodies. J Virol (1998) 2.64
Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci (2001) 2.60
Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci U S A (1991) 2.60
Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J Immunol (1990) 2.57
HIV-1 antibody--debris or virion? Nat Med (1997) 2.44
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol (1993) 2.42
Mutations of PVRL1, encoding a cell-cell adhesion molecule/herpesvirus receptor, in cleft lip/palate-ectodermal dysplasia. Nat Genet (2000) 2.39
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med (1997) 2.31
Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. J Virol (1987) 2.28
Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol (1998) 2.28
Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks. J Infect Dis (1986) 2.26
Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS (2000) 2.26
The structure of beta-lactoglobulin and its similarity to plasma retinol-binding protein. Nature (1987) 2.24
The role of the V3 loop of gp120 in HIV infection. AIDS (1991) 2.23
Bovine beta-lactoglobulin at 1.8 A resolution--still an enigmatic lipocalin. Structure (1997) 2.23
Do appointment systems work? Br Med J (Clin Res Ed) (1982) 2.22
Secondary-structure prediction from the sequence of Drosophila melanogaster (fruitfly) alcohol dehydrogenase. Biochem J (1980) 2.09
Interactions of human nuclear proteins P1Mcm3 and P1Cdc46. Eur J Biochem (1995) 2.03
Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci U S A (1993) 2.01
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol (1992) 1.94
Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A (1992) 1.93
Immunohistochemical localization of human and simian immunodeficiency viral antigens in fixed tissue sections. Am J Pathol (1987) 1.92
Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol (1999) 1.91
CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol (1995) 1.90
Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses (1996) 1.87
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol (1998) 1.87
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Diet, delusion and diabetes. Diabetologia (2009) 1.87
Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses (1997) 1.84
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Molecular aspects of healing in stabilized and non-stabilized fractures. J Orthop Res (2001) 1.75
Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol (1993) 1.70
Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol Immunol (1985) 1.68
Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature (1988) 1.67
The crystal structure of 8-amino-7-oxononanoate synthase: a bacterial PLP-dependent, acyl-CoA-condensing enzyme. J Mol Biol (1998) 1.67
Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. J Virol (1997) 1.66
Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis (1999) 1.65
Local retinoid signaling coordinates forebrain and facial morphogenesis by maintaining FGF8 and SHH. Development (2001) 1.63
Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol (1989) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F. AIDS Res Hum Retroviruses (1994) 1.59
Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1994) 1.57
Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology (1998) 1.57
Aspects of the molecular structure of IgG subclasses. Monogr Allergy (1986) 1.56
Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol (1999) 1.55
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci U S A (1992) 1.54
Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc Natl Acad Sci U S A (1991) 1.54
Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol (2001) 1.53
DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res (1998) 1.53
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Localisation of the monocyte-binding region on human immunoglobulin G. Mol Immunol (1986) 1.52
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol (1998) 1.51
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol (2001) 1.51
Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries. Nature (1992) 1.50
Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis (1988) 1.49